Many states have moved to enact mandatory pharmaceutical price disclosure laws that would increase price transparency to address prescription drug costs (Fig. 1, pg. 3). In 2018, states continued that trend, with 41 states having proposed plans to lower drug costs, including 23 considering transparency legislation.1, 2 Among the six states that passed legislation in 2018 were California and Oregon, notable not only for the pharmaceutical industry but also for the clients we serve.
The federal and state governments, holding differing views, have clashed over how to address prescription drug costs, leading legislators to propose hundreds of state laws aimed at lowering the cost of prescription drugs.
Price disclosure laws, while not directly targeted at lowering costs, will require transparency for certain price increases, which will reveal whether pricing has more to do with an assumption about a palatable price point than a pricing strategy based on science. These laws also may lead to increased pharmaceutical market competition.